106 / 140
Guía OncoSur de sarcomas de partes blandas
106
>
6. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose
ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13(7):1600.
7. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic
Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Random-
ized Multicenter Clinical Trial. J Clin Oncol 2016;34(8):786-93.
8. Van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a ran-
domised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
9. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with ad-
vanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet
2016;387(10028):1629.
10. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with
gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research
through Collaboration study 002. J Clin Oncol 2007;25:2755-63.
11. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone
versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Na-
tionale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Oncologist 2012;17:1213-20.
12. García del Muro X, López-Pousa A, Maurel J, et al (2011) Randomized phase II study comparing gemcitabine
plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish
Group for Research on Sarcomas study. J Clin Oncol 2011;29(18):2528.
13. Demetri G, Blay JY, Casali PG. Advances and controversies in the management of soft tissue sarcomas. Future
Oncology 2017;13(Suppl 1):3-11.